Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/RBM8A_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RBM8A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RBM8A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RBM8A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RBM8A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RBM8A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RBM8A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RBM8A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RBM8A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RBM8A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RBM8A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000640217 | Prostate | Tumor | mRNA catabolic process | 87/3246 | 232/18723 | 1.56e-13 | 1.73e-11 | 87 |
GO:000640117 | Prostate | Tumor | RNA catabolic process | 94/3246 | 278/18723 | 1.77e-11 | 1.25e-09 | 94 |
GO:000640317 | Prostate | Tumor | RNA localization | 70/3246 | 201/18723 | 1.58e-09 | 7.32e-08 | 70 |
GO:000095615 | Prostate | Tumor | nuclear-transcribed mRNA catabolic process | 46/3246 | 112/18723 | 2.80e-09 | 1.17e-07 | 46 |
GO:000038015 | Prostate | Tumor | alternative mRNA splicing, via spliceosome | 35/3246 | 77/18723 | 9.41e-09 | 3.55e-07 | 35 |
GO:000038115 | Prostate | Tumor | regulation of alternative mRNA splicing, via spliceosome | 29/3246 | 60/18723 | 3.18e-08 | 1.02e-06 | 29 |
GO:003465516 | Prostate | Tumor | nucleobase-containing compound catabolic process | 112/3246 | 407/18723 | 1.61e-07 | 4.02e-06 | 112 |
GO:004670014 | Prostate | Tumor | heterocycle catabolic process | 117/3246 | 445/18723 | 1.11e-06 | 2.10e-05 | 117 |
GO:004427015 | Prostate | Tumor | cellular nitrogen compound catabolic process | 118/3246 | 451/18723 | 1.30e-06 | 2.39e-05 | 118 |
GO:005123613 | Prostate | Tumor | establishment of RNA localization | 52/3246 | 166/18723 | 7.11e-06 | 1.07e-04 | 52 |
GO:190136114 | Prostate | Tumor | organic cyclic compound catabolic process | 124/3246 | 495/18723 | 7.37e-06 | 1.10e-04 | 124 |
GO:001943914 | Prostate | Tumor | aromatic compound catabolic process | 118/3246 | 467/18723 | 7.92e-06 | 1.17e-04 | 118 |
GO:005065713 | Prostate | Tumor | nucleic acid transport | 51/3246 | 163/18723 | 8.99e-06 | 1.32e-04 | 51 |
GO:005065813 | Prostate | Tumor | RNA transport | 51/3246 | 163/18723 | 8.99e-06 | 1.32e-04 | 51 |
GO:000018412 | Prostate | Tumor | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 16/3246 | 37/18723 | 2.07e-04 | 1.79e-03 | 16 |
GO:001593113 | Prostate | Tumor | nucleobase-containing compound transport | 59/3246 | 222/18723 | 3.49e-04 | 2.75e-03 | 59 |
GO:005102813 | Prostate | Tumor | mRNA transport | 38/3246 | 130/18723 | 5.44e-04 | 3.96e-03 | 38 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:190331125 | Skin | AK | regulation of mRNA metabolic process | 81/1910 | 288/18723 | 7.27e-18 | 8.61e-15 | 81 |
GO:004348428 | Skin | AK | regulation of RNA splicing | 54/1910 | 148/18723 | 9.66e-18 | 9.53e-15 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RBM8A | SNV | Missense_Mutation | novel | c.488G>A | p.Arg163Gln | p.R163Q | Q9Y5S9 | protein_coding | tolerated(0.12) | possibly_damaging(0.885) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | | c.16N>A | p.Asp6Asn | p.D6N | Q9Y5S9 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
RBM8A | SNV | Missense_Mutation | | c.76N>T | p.His26Tyr | p.H26Y | Q9Y5S9 | protein_coding | deleterious(0.04) | benign(0.358) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
RBM8A | SNV | Missense_Mutation | | c.194N>T | p.Gly65Val | p.G65V | Q9Y5S9 | protein_coding | deleterious(0) | benign(0.206) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD |
RBM8A | SNV | Missense_Mutation | | c.467A>C | p.Lys156Thr | p.K156T | Q9Y5S9 | protein_coding | tolerated(0.16) | benign(0.227) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | | c.444G>C | p.Trp148Cys | p.W148C | Q9Y5S9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EF-5830-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | | c.454N>T | p.Arg152Trp | p.R152W | Q9Y5S9 | protein_coding | tolerated(0.09) | benign(0) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | | c.454N>T | p.Arg152Trp | p.R152W | Q9Y5S9 | protein_coding | tolerated(0.09) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | novel | c.275N>C | p.Lys92Thr | p.K92T | Q9Y5S9 | protein_coding | tolerated(0.09) | benign(0.068) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RBM8A | SNV | Missense_Mutation | | c.521N>A | p.Arg174His | p.R174H | Q9Y5S9 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |